Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients

Background: With the integration of various targeted therapies into the clinical management of patients with advanced lung adenocarcinoma, next-generation sequencing (NGS) has become the technology of choice and has led to an increase in simultaneously interrogated genes. However, the broader adoption of NGS for routine clinical practice is still hampered by sophisticated workflows, complex bioinformatics analysis and medical interpretation. Therefore, the performance of the novel QIAGEN GeneReader NGS system was compared to an in-house ISO-15189 certified Ion PGM NGS platform. Methods: Clinical samples from 90 patients (60 Retrospectively and 30 Prospectively) with lung adenocarcinoma were sequenced with both systems. Mutations were analyzed and EGFR, KRAS, BRAF, NRAS, ALK, PIK3CA and ERBB2 genes were compared and sampling time and suitability for clinical testing were assessed. Results: Both sequencing systems showed perfect concordance for the overlapping genes. Correlation of allele frequency was r2 = 0.93 for the retrospective patients and r2 = 0.81 for the prospective patients. Hands-on time and total run time were shorter using the PGM system, while the GeneReader platform provided good traceability and up-to-date interpretation of the results. Conclusion: We demonstrated the suitability of the GeneReader NGS system in routine practice in a clinical pathology laboratory setting.

[1]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Czirók,et al.  Cell Dispersal Influences Tumor Heterogeneity and Introduces a Bias in NGS Data Interpretation , 2017, Scientific Reports.

[3]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[4]  Anne-Mette K. Hein,et al.  Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform , 2017, BMC Cancer.

[5]  C. Marquette,et al.  NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype? , 2017, Expert review of anticancer therapy.

[6]  Yoon-La Choi,et al.  Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests , 2017, Journal of pathology and translational medicine.

[7]  Yi Kong,et al.  Use of the GeneReader NGS System in a clinical pathology laboratory: a comparative study , 2017, Journal of Clinical Pathology.

[8]  Steven E. Schild,et al.  Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology , 2017 .

[9]  P. Brousset,et al.  High-throughput detection of clinically targetable alterations using next-generation sequencing , 2017, Oncotarget.

[10]  Christoph Endrullat,et al.  Standardization and quality management in next-generation sequencing , 2016, Applied & translational genomics.

[11]  G. Sica,et al.  Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies. , 2016, The Journal of molecular diagnostics : JMD.

[12]  C. Schumann,et al.  Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. , 2015, The oncologist.

[13]  S. Peters,et al.  BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  R. McCormack,et al.  EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). , 2015, American journal of cancer research.

[15]  M. Koudijs,et al.  Comparison of next-generation sequencing and mutation-specific platforms in clinical practice. , 2015, American journal of clinical pathology.

[16]  Leslie Cope,et al.  Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. , 2014, American journal of clinical pathology.

[17]  Rashmi Kanagal-Shamanna,et al.  Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. , 2013, The Journal of molecular diagnostics : JMD.

[18]  R. Sinke,et al.  Targeted Next‐Generation Sequencing can Replace Sanger Sequencing in Clinical Diagnostics , 2013, Human mutation.

[19]  Tina Hambuch,et al.  Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the Association for Molecular Pathology. , 2012, The Journal of molecular diagnostics : JMD.

[20]  L. Spaggiari,et al.  Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  P. Hofman,et al.  Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma , 2010, Virchows Archiv.

[22]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[23]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[24]  Renato Martins,et al.  Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[25]  Hong-lei Chen,et al.  Comparison of two methods to extract DNA from formalin-fixed, paraffin-embedded tissues and their impact on EGFR mutation detection in non-small cell lung carcinoma. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[26]  Savita Shrivastava,et al.  Validation of a next-generation sequencing assay for clinical molecular oncology. , 2014, The Journal of molecular diagnostics : JMD.

[27]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .